RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Recordati Industria Chimica e Farmaceutica SpA Stock

Recordati Industria Chimica e Farmaceutica SpA EBIT 2024

Recordati Industria Chimica e Farmaceutica SpA EBIT

683.95 M EUR

Ticker

REC.MI

ISIN

IT0003828271

WKN

A0EABR

In 2024, Recordati Industria Chimica e Farmaceutica SpA's EBIT was 683.95 M EUR, a 20.41% increase from the 568.02 M EUR EBIT recorded in the previous year.

The Recordati Industria Chimica e Farmaceutica SpA EBIT history

YEAREBIT (undefined EUR)
2029e-
2028e995.75
2027e925.66
2026e847.19
2025e789.86
2024e683.95
2023568.02
2022494.81
2021504.67
2020473.94
2019465.53
2018445.75
2017408.74
2016340.05
2015282.23
2014235.55
2013209.2
2012183.6
2011163.5
2010154.8
2009162.2
2008144.7
2007131.5
2006120.3
2005111.1
200493.9

Recordati Industria Chimica e Farmaceutica SpA Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Recordati Industria Chimica e Farmaceutica SpA, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Recordati Industria Chimica e Farmaceutica SpA from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Recordati Industria Chimica e Farmaceutica SpA’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Recordati Industria Chimica e Farmaceutica SpA. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Recordati Industria Chimica e Farmaceutica SpA’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Recordati Industria Chimica e Farmaceutica SpA’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Recordati Industria Chimica e Farmaceutica SpA’s growth potential.

Recordati Industria Chimica e Farmaceutica SpA Revenue, EBIT and net profit per share

DateRecordati Industria Chimica e Farmaceutica SpA RevenueRecordati Industria Chimica e Farmaceutica SpA EBITRecordati Industria Chimica e Farmaceutica SpA Net Income
2029e2.89 B undefined0 undefined0 undefined
2028e3.07 B undefined995.75 M undefined847.48 M undefined
2027e2.94 B undefined925.66 M undefined776.62 M undefined
2026e2.73 B undefined847.19 M undefined618.92 M undefined
2025e2.59 B undefined789.86 M undefined566.37 M undefined
2024e2.35 B undefined683.95 M undefined494.6 M undefined
20232.08 B undefined568.02 M undefined389.21 M undefined
20221.85 B undefined494.81 M undefined312.34 M undefined
20211.58 B undefined504.67 M undefined385.97 M undefined
20201.45 B undefined473.94 M undefined354.98 M undefined
20191.48 B undefined465.53 M undefined368.83 M undefined
20181.35 B undefined445.75 M undefined312.38 M undefined
20171.29 B undefined408.74 M undefined288.76 M undefined
20161.15 B undefined340.05 M undefined237.41 M undefined
20151.05 B undefined282.23 M undefined198.79 M undefined
2014987.36 M undefined235.55 M undefined161.19 M undefined
2013941.6 M undefined209.2 M undefined133.7 M undefined
2012828.3 M undefined183.6 M undefined118.5 M undefined
2011762 M undefined163.5 M undefined116.4 M undefined
2010728.1 M undefined154.8 M undefined108.6 M undefined
2009747.5 M undefined162.2 M undefined110.6 M undefined
2008689.6 M undefined144.7 M undefined100.4 M undefined
2007628.4 M undefined131.5 M undefined84.9 M undefined
2006576.2 M undefined120.3 M undefined74 M undefined
2005576.1 M undefined111.1 M undefined64.5 M undefined
2004488.3 M undefined93.9 M undefined54 M undefined

Recordati Industria Chimica e Farmaceutica SpA stock margins

The Recordati Industria Chimica e Farmaceutica SpA margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Recordati Industria Chimica e Farmaceutica SpA. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Recordati Industria Chimica e Farmaceutica SpA.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Recordati Industria Chimica e Farmaceutica SpA's sales revenue. A higher gross margin percentage indicates that the Recordati Industria Chimica e Farmaceutica SpA retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Recordati Industria Chimica e Farmaceutica SpA's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Recordati Industria Chimica e Farmaceutica SpA's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Recordati Industria Chimica e Farmaceutica SpA's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Recordati Industria Chimica e Farmaceutica SpA. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Recordati Industria Chimica e Farmaceutica SpA's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Recordati Industria Chimica e Farmaceutica SpA Margin History

Recordati Industria Chimica e Farmaceutica SpA Gross marginRecordati Industria Chimica e Farmaceutica SpA Profit marginRecordati Industria Chimica e Farmaceutica SpA EBIT marginRecordati Industria Chimica e Farmaceutica SpA Profit margin
2029e68.32 %0 %0 %
2028e68.32 %32.49 %27.65 %
2027e68.32 %31.53 %26.45 %
2026e68.32 %30.99 %22.64 %
2025e68.32 %30.48 %21.86 %
2024e68.32 %29.07 %21.02 %
202368.32 %27.28 %18.69 %
202269.42 %26.7 %16.85 %
202172.93 %31.94 %24.43 %
202071.92 %32.71 %24.5 %
201970.52 %31.42 %24.89 %
201870.75 %32.96 %23.1 %
201770.29 %31.73 %22.42 %
201668.72 %29.47 %20.57 %
201568 %26.94 %18.97 %
201466.88 %23.86 %16.33 %
201365.24 %22.22 %14.2 %
201264.57 %22.17 %14.31 %
201165.89 %21.46 %15.28 %
201067.04 %21.26 %14.92 %
200968.48 %21.7 %14.8 %
200867.78 %20.98 %14.56 %
200767.17 %20.93 %13.51 %
200666.68 %20.88 %12.84 %
200565.18 %19.28 %11.2 %
200463.28 %19.23 %11.06 %

Recordati Industria Chimica e Farmaceutica SpA Aktienanalyse

What does Recordati Industria Chimica e Farmaceutica SpA do?

Recordati Industria Chimica e Farmaceutica SpA is an Italian pharmaceutical company based in Milan. The company was founded in 1926 by Giovanni Recordati and now has branches in many countries worldwide. Recordati's business model is based on the development, production, and marketing of drugs for various therapeutic areas. The company focuses particularly on therapy areas such as cardiology, urology, gastroenterology, pneumology, and hematology. Recordati operates in four business areas: Innovative Medicines, OTC Medicines, Generics, and Licensed Products. In the area of innovative medicines, the company specializes in the development of new active substances for the treatment of rare diseases. In the OTC Medicines area, Recordati specializes in the manufacture and marketing of over-the-counter drugs used to treat mild to moderate complaints. The generics area includes the production and marketing of generic products with the aim of influencing price development in the market. In the Licensed Products area, Recordati collaborates with other companies and takes over the marketing of their products in certain regions. Some of Recordati's best-known products include Cariprazine (an antipsychotic), Urolith (a preventive treatment for kidney stones), Zanipress (a treatment for hypertension), and Fokusin (a treatment for benign prostatic hyperplasia). Recordati is also committed to improving access to life-saving medications worldwide. The company engages in collaborations with international organizations such as the Global Alliance for TB Drug Development and supports the WHO's "Target Product Profiles" initiative. In 2019, Recordati Industria Chimica e Farmaceutica SpA achieved sales of around 1.4 billion euros in over 90 countries. The company employs about 4,200 people worldwide, including approximately 500 researchers and developers. In terms of future direction, Recordati sees continued high potential for growth and expansion, particularly through targeted investments in research and development. The company relies on close cooperation with other partners within the industry and the exploration of new markets and therapeutic areas. Recordati Industria Chimica e Farmaceutica SpA ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Recordati Industria Chimica e Farmaceutica SpA's EBIT

Recordati Industria Chimica e Farmaceutica SpA's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Recordati Industria Chimica e Farmaceutica SpA's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Recordati Industria Chimica e Farmaceutica SpA's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Recordati Industria Chimica e Farmaceutica SpA’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Recordati Industria Chimica e Farmaceutica SpA stock

How much did Recordati Industria Chimica e Farmaceutica SpA achieve in EBIT for the current year?

In the current year, Recordati Industria Chimica e Farmaceutica SpA has achieved an EBIT of 683.95 M EUR.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Recordati Industria Chimica e Farmaceutica SpA.

How has the EBIT of Recordati Industria Chimica e Farmaceutica SpA developed in recent years?

The EBIT of Recordati Industria Chimica e Farmaceutica SpA has increased by 20.411% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Recordati Industria Chimica e Farmaceutica SpA?

The EBIT of Recordati Industria Chimica e Farmaceutica SpA is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Recordati Industria Chimica e Farmaceutica SpA pay?

Over the past 12 months, Recordati Industria Chimica e Farmaceutica SpA paid a dividend of 1.17 EUR . This corresponds to a dividend yield of about 2.3 %. For the coming 12 months, Recordati Industria Chimica e Farmaceutica SpA is expected to pay a dividend of 1.25 EUR.

What is the dividend yield of Recordati Industria Chimica e Farmaceutica SpA?

The current dividend yield of Recordati Industria Chimica e Farmaceutica SpA is 2.3 %.

When does Recordati Industria Chimica e Farmaceutica SpA pay dividends?

Recordati Industria Chimica e Farmaceutica SpA pays a quarterly dividend. This is distributed in the months of June, December, June, December.

How secure is the dividend of Recordati Industria Chimica e Farmaceutica SpA?

Recordati Industria Chimica e Farmaceutica SpA paid dividends every year for the past 0 years.

What is the dividend of Recordati Industria Chimica e Farmaceutica SpA?

For the upcoming 12 months, dividends amounting to 1.25 EUR are expected. This corresponds to a dividend yield of 2.45 %.

In which sector is Recordati Industria Chimica e Farmaceutica SpA located?

Recordati Industria Chimica e Farmaceutica SpA is assigned to the 'Health' sector.

Wann musste ich die Aktien von Recordati Industria Chimica e Farmaceutica SpA kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Recordati Industria Chimica e Farmaceutica SpA from 11/20/2024 amounting to 0.6 EUR, you needed to have the stock in your portfolio before the ex-date on 11/18/2024.

When did Recordati Industria Chimica e Farmaceutica SpA pay the last dividend?

The last dividend was paid out on 11/20/2024.

What was the dividend of Recordati Industria Chimica e Farmaceutica SpA in the year 2023?

In the year 2023, Recordati Industria Chimica e Farmaceutica SpA distributed 1.12 EUR as dividends.

In which currency does Recordati Industria Chimica e Farmaceutica SpA pay out the dividend?

The dividends of Recordati Industria Chimica e Farmaceutica SpA are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Recordati Industria Chimica e Farmaceutica SpA

Our stock analysis for Recordati Industria Chimica e Farmaceutica SpA Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Recordati Industria Chimica e Farmaceutica SpA Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.